January 14, 2025 Acad, Gov/Utilities Clinical Research/Diagn. Lab Top-10 Life Science Tools

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics. The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying... Read more

January 8, 2025 Clinical Research/Diagn. Licensing, IP, and Legal Microscopy

PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets

MENLO PARK, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, has delivered its first Vega systems to Berry Genomics as part of an early access agreement announced in 2022. Under the terms of the original agreement, Berry Genomics will develop and optimize its targeted assays... Read more

December 18, 2024 Clinical Research/Diagn. Environ, Ag./Food & Bev Mass Spectrometry

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the routine clinical lab Clinical mass spectrometry testing offers unparalleled sensitivity and specificity, providing clinicians with additional diagnostic insights1 cobas Mass Spec solution will offer a fully automated, integrated and standardised workflow with IVDR-compliant assays Basel, 18 December 2024 – Roche (SIX: RO, ROG;... Read more

December 9, 2024 Clinical Research/Diagn.

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

Basel, 9 December 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (Poseida) (NASDAQ: PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain contingent... Read more

November 26, 2024 Clinical Research/Diagn. M&A, Partnerships

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies Roche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US... Read more

October 31, 2024 Clinical Research/Diagn. Product Launch

Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s disease related amyloid pathology with very good accuracy. In the largest worldwide clinical trial of its kind, the blood-based test showed very good accuracy in ruling out Alzheimer’s pathology in those being investigated for the disease,... Read more

September 4, 2024 Acad, Gov/Utilities Atomic Spectroscopy Clinical Research/Diagn.

Revio to Power Research in Male Infertility and Rare Disease at Münster University Hospital

MENLO PARK, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with the University Hospital of Münster, to use long-read whole genome sequencing to significantly advance male infertility and rare disease research. By deploying PacBio’s Revio HiFi sequencing system, researchers at... Read more

August 26, 2024 Clinical Research/Diagn. Lab Top-10

Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.

Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C. WASHINGTON, Aug. 26, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery,... Read more

July 17, 2024 Clinical Research/Diagn. Lab Top-10 Product Launch

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together... Read more